RBC Capital Maintains Outperform on Nurix Therapeutics, Raises Price Target to $36
RBC Capital analyst Brian Abrahams maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $33 to $36.
Stocks · News reference
Nurix Therapeutics Earns $10M Milestone Payment Following Initiation Of Sanofi's Phase 1 Clinical Study Of SAR448272/NX-3911
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that it has
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Needham Reiterates Buy on Nurix Therapeutics, Maintains $34 Price Target
Needham analyst Gil Blum reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $34 price target.
Nurix Therapeutics Enrolls First Patient In Registrational Phase 3 DAYBreak CLL-306 Trial Of Bexobrutideg For Relapsed/Refractory CLL/SLL
Does Moderna's mRNA Flu Shot Face a New Challenge From GSK?
Moderna secured FDA approval for mFlusiva, the first mRNA-based seasonal flu vaccine, establishing a foothold in the multibillion-dollar flu vaccine market. However, GSK announced plans to advance its own mRNA flu vaccine into phase III trials, which targets two viral proteins (HA and NA) and showed superior immune responses in phase II studies. While GSK's vaccine is still years away from market approval, it could pose a competitive challenge to Moderna's mFlusiva, which currently targets only HA like traditional flu vaccines.
Eli Lilly to Buy Immunology Biotech Merida Biosciences in $2.9B Deal
Eli Lilly announced a definitive agreement to acquire clinical-stage biotech Merida Biosciences for up to $2.875 billion in an all-cash transaction. The deal adds MER511 for Graves' disease and thyroid eye disease, along with preclinical candidates for allergy and kidney disease. This acquisition marks Lilly's 10th major deal in 2026 as the company diversifies its pipeline beyond cardiometabolic medicines, leveraging strong cash generation from its blockbuster GLP-1 drugs.
The Multiple Sclerosis Drug Race Just Got Hotter After Novartis’ Phase 3 Win
Novartis stock spikes 5% on positive Phase 3 REMODEL trial results for relapsing MS drug remibrutinib with no liver safety signals.